Please use this identifier to cite or link to this item:
|Title:||Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer.||Austin Authors:||Alberto, Matthew;Yim, Arthur;Papa, Nathan;Siva, Shankar;Ischia, Joseph J ;Touijer, Karim;Eastham, James A;Bolton, Damien M ;Perera, Marlon||Affiliation:||Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Department of Preventive Medicine, Monash University, Melbourne, VIC, Australia
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Surgery (University of Melbourne)
|Issue Date:||2022||Date:||2022||Publication information:||Frontiers in Oncology 2022; 12: 929444||Abstract:||Oligometastatic prostate cancer (OMPC) has been proposed as an intermediary state between localised disease and widespread metastases, with varying definitions including 1, 3, or ≤5 visceral or bone metastasis. Traditional definitions of OMPC are based on staging with conventional imaging, such as computerised tomography (CT) and whole-body bone scan (WBBS). Novel imaging modalities such as prostate-specific membrane antigen positron emission tomography (PSMA PET) have improved diagnostic utility in detecting early metastatic prostate cancer (PC) metastases compared with conventional imaging. Specifically, meta-analytical data suggest that PSMA PET is sensitive in detecting oligometastatic disease in patients with biochemical recurrence (BCR) post-radical treatment of PC. Recent trials have evaluated PSMA PET-guided metastases-directed therapy (MDT) in oligometastatic recurrent disease, typically with salvage surgery or radiotherapy (RT). To date, these preliminary studies demonstrate promising results, potentially delaying the need for systemic therapy. We aim to report a comprehensive, multidisciplinary review of PSMA-guided MDT in OMPC. In this review, we highlight the utility of PMSA PET in biochemically recurrent disease and impact of PSMA PET on the definition of oligometastatic disease and outline data pertaining to PSMA-guided MDT.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/30873||DOI:||10.3389/fonc.2022.929444||Journal:||Frontiers in Oncology||PubMed URL:||36059632||ISSN:||2234-943X||Type:||Journal Article||Subjects:||PSMA PET
metastastases directed therapy
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 2, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.